Robert W. Baird Boosts MEDNAX (MD) Price Target to $54.00
MD has been the subject of a number of other research reports. Stephens set a $62.00 target price on shares of MEDNAX and gave the company a buy rating in a research report on Thursday. Citigroup decreased their target price on shares of MEDNAX from $52.00 to $47.00 and set a neutral rating for the company in a research report on Friday, November 3rd. Zacks Investment Research raised shares of MEDNAX from a hold rating to a buy rating and set a $60.00 target price for the company in a research report on Tuesday, January 23rd. Jefferies Group set a $50.00 target price on shares of MEDNAX and gave the company a hold rating in a research report on Tuesday. Finally, Stifel Nicolaus reissued a hold rating and set a $56.00 target price on shares of MEDNAX in a research report on Wednesday, January 24th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and four have issued a buy rating to the company. The company presently has a consensus rating of Hold and an average target price of $55.08.
MEDNAX (NYSE:MD) traded up $1.38 during trading hours on Friday, reaching $53.94. 1,694,384 shares of the company were exchanged, compared to its average volume of 857,284. MEDNAX has a 12 month low of $40.56 and a 12 month high of $72.13. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.43 and a quick ratio of 1.37. The stock has a market capitalization of $4,922.52, a PE ratio of 15.63, a price-to-earnings-growth ratio of 1.45 and a beta of 0.31.
In other MEDNAX news, insider John C. Pepia sold 3,000 shares of the firm’s stock in a transaction on Tuesday, December 12th. The shares were sold at an average price of $51.58, for a total value of $154,740.00. Following the completion of the transaction, the insider now owns 35,569 shares of the company’s stock, valued at $1,834,649.02. The transaction was disclosed in a filing with the SEC, which is available at this link. Company insiders own 2.40% of the company’s stock.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Prudential Financial Inc. raised its holdings in shares of MEDNAX by 976.9% in the third quarter. Prudential Financial Inc. now owns 641,057 shares of the company’s stock worth $27,642,000 after buying an additional 581,527 shares during the last quarter. Quantbot Technologies LP purchased a new position in shares of MEDNAX in the third quarter worth $695,000. Point72 Asset Management L.P. raised its holdings in shares of MEDNAX by 71.7% in the third quarter. Point72 Asset Management L.P. now owns 132,700 shares of the company’s stock worth $5,722,000 after buying an additional 55,400 shares during the last quarter. Nomura Holdings Inc. purchased a new position in shares of MEDNAX in the second quarter worth $347,000. Finally, Advisor Group Inc. raised its holdings in shares of MEDNAX by 41.9% in the third quarter. Advisor Group Inc. now owns 8,361 shares of the company’s stock worth $359,000 after buying an additional 2,468 shares during the last quarter. 98.67% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: This piece was published by Watch List News and is owned by of Watch List News. If you are viewing this piece on another site, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be read at https://www.watchlistnews.com/robert-w-baird-boosts-mednax-md-price-target-to-54-00/1857556.html.
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.